8-K filed November 21, 2023, 6:59 PM ET CIK 0001600132

leadership confidence high sentiment negative materiality 0.85

Bellerophon appoints Craig Jalbert President/principal officer amid wind-down; CEO leaves Nov 15

Bellerophon Therapeutics, Inc.

CEO Peter Fernandes and VP Parag Shah separated effective Nov 15, 2023, per previously disclosed separation agreements.
Craig Jalbert appointed President, Treasurer, Corporate Secretary, principal executive/financial/accounting officer, and director.
Jalbert, a distressed-business specialist at Verdolino & Lowey, will be compensated $10k/month pre-dissolution, then $50k/year for three years post-dissolution.
Compensation structure is contingent on stockholder approval of dissolution and board decision to implement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Craig Jalbert

Director

Bellerophon Therapeutics, Inc.

Effective: 2023-11-15
Filed: November 21, 2023, 6:59 PM ET

On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023

Appointed

Craig Jalbert

President

Bellerophon Therapeutics, Inc.

Effective: 2023-11-15
Filed: November 21, 2023, 6:59 PM ET

On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023

Departed

Peter Fernandes

Chief Executive Officer

Bellerophon Therapeutics, Inc.

Effective: 2023-11-15
Successor: Craig Jalbert
Filed: November 21, 2023, 6:59 PM ET

the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.

Departed

Parag Shah

Vice President of Business Operations

Bellerophon Therapeutics, Inc.

Effective: 2023-11-15
Filed: November 21, 2023, 6:59 PM ET

the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Craig Jalbert was appointed as Director at Bellerophon Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Craig Jalbert was appointed as President at Bellerophon Therapeutics, Inc..

Action: appointed
Role: President

Exact text from the filing

On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Peter Fernandes departed as Chief Executive Officer at Bellerophon Therapeutics, Inc..

Action: separated
Role: Chief Executive Officer

Exact text from the filing

the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Parag Shah departed as Vice President of Business Operations at Bellerophon Therapeutics, Inc..

Action: separated
Role: Vice President of Business Operations

Exact text from the filing

the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-120348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.